| Description |
1 online resource (358 pages) : illustrations |
| Contents |
Cover; Title page; Copyright page; Contents; List of Contributors; Acknowledgments; Chapter 1 -- Current Trends in Cancer Therapy; PI3K/AKT pathway; Idelelasib; mTOR pathway; mTOR Inhibitors; Temsirolimus; Everolimus; Mitogen-activated protein kinase (MAPK) pathway; RAF Inhibitors; Vemurafenib; Dabrafenib; Sorafenib; MEK Inhibitors; Trametinib; Combination of MEK and BRAF inhibitors; EGFR pathway; EGFR Tyrosine Kinase Inhibitors; Gefitinib; Erlotinib; Afatinib; EGFR Monoclonal Antibodies; Panitumumab; Cetuximab; Human epidermal growth factor receptor 2; Trastuzumab; Pertuzumab; Lapatinib |
|
Ado Trastuzumab EmtansineAnaplastic lymphoma kinase pathway; Crizotinib; Ceritinib; Antiangiogenic agents; VEGF pathway; VEGF Monoclonal Antibodies; Bevacizumab; Ramucirumab; VEGF Tyrosine Kinase Inhibitors; Sunitinib; Sorafenib; Pazopanib; Axitinib; Vandetinib; Cabozantinib; Regorafenib; Immunotherapy; Cancer Vaccines; Sipuleucel-T; Adoptive T Cell Immunotherapy; Immune Checkpoint Blockade; CTLA-4 Inhibition; Ipilimumab; PD1/PDL1/PDL2 Inhibition; Nivolumab; Pembroluzimab; Toxicities of Immune Checkpoint Inhibitions; Monitoring Response in Checkpoint Inhibition; Combination Therapy |
|
Future DirectionsCyclin dependent kinases and their pathways; Palbociclib; Poly ADP ribose polymerase inhibition; Olaparib; Conclusions; References; Chapter 2 -- Molecular Mechanisms Underlying Anthracycline Cardiotoxicity: Challenges in Cardio-Oncology; Introduction; Impaired redox signaling; Iron overload in mitochondria; Calcium overload in mitochondria; Altered mitochondrial dynamics in anthracyclines; Respiratory defects and altered metabolism in anthracycline cardiotoxicity; Autophagy in anthracycline cardiotoxicity |
|
Deregulated molecular signaling pathways in anthracycline cardiotoxicityGender-specific cardiotoxic effects of anthracycline; Anthracyclines and cardiac remodeling; Strategies to prevent doxorubicin cardiotoxicity; Conclusions; References; Chapter 3 -- Common Pathways in Cancer, Tumor Angiogenesis and Vascular Disease; Introduction; Hedgehog signaling; Notch signaling; Vascular targets for chemotherapy-angiogenesis; Vascular targets for chemotherapy-vasculogenic mimicry; Vascular targets for chemotherapy-microvesicular trafficking; Vascular targets for chemotherapy-vessel maturation |
|
Hedgehog and cancer biologyHedgehog inhibitors in cancer therapy; Hedgehog and vascular biology; Notch signaling and tumor biology; Notch inhibitors; Notch signaling and vascular biology; Chemotherapy and vascular disease; Conclusions; References; Chapter 4 -- Molecular Mechanisms of Anthracycline-Induced Cardiotoxicity; Historical and clinical perspectives; Risk factors; Molecular mechanisms of DOX mediated cardiotoxicity; Reactive Oxygen Species Production; Enzymatic Reaction; DOX-Fe Complexes; DOX/DNA/Top-II Beta Ternary Complex; Strategies to limit anthracycline toxicities |
| Bibliography |
Includes bibliographical references and index |
| Subject |
Heart -- Cancer
|
|
Heart Diseases -- etiology
|
|
Heart Neoplasms
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Heart -- Cancer
|
| Form |
Electronic book
|
| Author |
Mehta, Puja K., author
|
| ISBN |
9780128035535 |
|
0128035536 |
|
